Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 14/20 | 0.47 |
| ▸ | BRAF | P15056 | 14/20 | 0.47 |
| ▸ | GBA1 | P04062 | 4/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425521 | 0.94 | RAF1 (0.51) | RAF1BRAFGBA1KDM4EALDH1A1 | |
| SCHEMBL11926320 | 0.91 | GBA1 (0.45) | RAF1BRAFGBA1GLAKDM4E | |
| SCHEMBL11926325 | 0.90 | RAF1 (0.45) | RAF1BRAFGBA1GLAKDM4E | |
| SCHEMBL3114692 | 0.90 | RAF1 (0.50) | RAF1BRAFGBA1KDM4EMAPT | |
| SCHEMBL11926334 | 0.88 | RAF1 (0.49) | RAF1BRAFGBA1GLAKDM4E | |
| SCHEMBL3111833 | 0.88 | RAF1 (0.47) | RAF1BRAFGBA1KDM4EALDH1A1 | |
| SCHEMBL1271438 | 0.87 | RAF1 (0.45) | RAF1BRAFGBA1GLAKDM4E | |
| SCHEMBL11926321 | 0.87 | GAA (0.48) | RAF1BRAFGBA1GLAKDM4E | |
| SCHEMBL11926275 | 0.86 | RAD52 (0.46) | RAF1BRAFGBA1KDM4EALDH1A1 | |
| SCHEMBL11926283 | 0.86 | RAF1 (0.47) | RAF1BRAFGBA1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | RAF1 2782/4885BRAF 2713/4885GBA1 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.